Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

The MADE (Minocycline in Alzheimer’s Disease Efficacy trial) is a double-blind randomised trial that aims to provide reliable evidence on the effects of minocycline in slowing the progress of Alzheimer’s disease (AD).

Minocycline is an antibiotic medication used most commonly to treat infections and acne. Laboratory research suggests that minocycline might also slow the progress of AD and this is what the MADE trial aims to find out.

AD is a huge public health problem, with approximately 700,000 people in the UK suffering from dementia of whom some 400,000 have Alzheimer’s disease. At the moment, there are no drugs that slow disease progress. So, if this inexpensive and well tolerated drug is shown to be neuroprotective this would make a huge difference to treatment of people with AD worldwide.

MADE is funded by the UK Medical Research Council and aims to recruit approximately 560 people with very mild AD. MADE volunteers will be randomly allocated to two years of treatment with 400mg of minocycline, 200mg of minocycline or matching placebo. The primary outcomes are decline in cognitive and functional ability.

Please contact for further information.

Related research themes